05-636-AF488
抗磷酸化组蛋白H2A.X (Ser139) ，克隆JBW301，Alexa Fluor™ 488 结合抗体
clone JBW301, from mouse, ALEXA FLUOR™ 488
别名:
Histone H2AX, H2a/x, Histone H2A.X
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
ALEXA FLUOR™ 488
Clone:
JBW301, monoclonal
Application:
ICC
Citations:
19
biological source
mouse
Quality Level
conjugate
ALEXA FLUOR™ 488
antibody form
purified antibody
antibody product type
primary antibodies
clone
JBW301, monoclonal
species reactivity
human
species reactivity (predicted by homology)
vertebrates (based on 100% sequence homology)
technique(s)
immunocytochemistry: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer139)
Gene Information
human ... H2AX(3014)
General description
组蛋白H2A.X是组蛋白H2A的变体，与基因组DNA相似。但是，组蛋白在结构上与H2A家族的其他成员不同，因为它具有一个C末端尾巴，该尾巴包含Ser139残基，该残基响应于双链DNA的断裂而被磷酸化。H2A.X的磷酸化是由ATM/ATR蛋白介导的快速过程。
计算分子量为17 kDa
Application
该抗磷酸化组蛋白H2A.X（Ser139）抗体（克隆JBW301，Alexa Fluor™ 488偶联物）经验证可用于ICC检测磷酸化组蛋白H2A.X（Ser139）。
Analysis Note
通过免疫细胞化学在未处理（阴性对照）和星形孢菌素处理的HeLa细胞中进行评估。
免疫细胞化学分析：来自代表性批次的1:100稀释液在星形孢菌素处理的HeLa细胞中检测到磷酸组蛋白H2A.X（Ser139），而在未处理的HeLa细胞中未检测到。
免疫细胞化学分析：来自代表性批次的1:100稀释液在星形孢菌素处理的HeLa细胞中检测到磷酸组蛋白H2A.X（Ser139），而在未处理的HeLa细胞中未检测到。
Other Notes
浓度：请参考批次特异性浓缩物的分析证书。
Legal Information
ALEXA FLUOR is a trademark of Life Technologies
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Lara H El Touny et al.
Oncotarget, 12(21), 2114-2130 (2021-10-23)
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/-ve/MMRproficient patients benefit from TMZ treatment, indicating a need for
Jolien Van den Bossche et al.
Cancers, 11(12) (2019-12-05)
Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division, is highly expressed in non-small cell lung cancer (NSCLC) making it an interesting drug target. We examined the in vitro therapeutic effects of volasertib, a Plk1 inhibitor, in combination
Lazina Hossain et al.
International journal of molecular sciences, 25(14) (2024-07-27)
Secondary lymphedema is caused by damage to the lymphatic system from surgery, cancer treatment, infection, trauma, or obesity. This damage induces stresses such as oxidative stress and hypoxia in lymphatic tissue, impairing the lymphatic system. In response to damage, vascular
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 05-636-AF488 | 04053252971907 |